AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
List view / Grid view
Filter the results
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
In this article, Alison Bourke, Scientific Director of the Center for Advanced Evidence Generation at IQVIA Health, explores how digitally-connected active and passive data sources are shaping the development of patient-centric treatments and care.
The FDA has approved Aurinia Pharmaceuticals' LupkynisTM(voclosporin) for the treatment of lupus nephritis, alongside standard-of-care.
The approval of Cabenuva (cabotegravir and rilpivirine, injectable formulation) means HIV infected adults could receive once-monthly injections to manage their condition.
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
13 January 2021 | By Altasciences
Join us on 9 March 2021 at 14:00 GMT for an overview of a foreign health authority’s requirements for gaining approval to conduct an FIH clinical trial by comparing Health Canada and European Medicines Agency (EMA) Clinical Trial Authorisation (CTA) processes to that of the FDA IND submission.
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
Synairgen's interferon beta therapy is being studied as a potential COVID-19 treatment in a Phase III trial as the first patient is dosed.